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Background: Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen
4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) produce unique toxicity profiles. The objective of this
review was to identify patterns and incidence of immune-related adverse events (irAE) based on tumour type and ICI class.
Methods: Medline, EMBASE and COCHRANE databases were searched to identify prospective monotherapy trials of ICIs from
2003 to November 2015. Paired reviewers selected studies for inclusion and extracted data. Odds ratio (OR), v2 tests and
multivariable regression models were used to analyse for effect size and associations.
Results: We identified 48 trials (6938 patients), including 26 CTLA-4, 17 PD-1, 2 PD-L1 trials, and 3 studies tested both CTLA-4 and
PD-1. Grade 3/4 irAE were more common with CTLA-4 mAbs compared with PD-1 (31% versus 10%). All grades colitis (OR 8.7, 95%
CI 5.8–12.9), hypophysitis (OR 6.5, 95% CI 3.0–14.3) and rash (OR 2.0, 95% CI 1.8–2.3) were more frequent with CTLA-4 mAbs;
whereas pneumonitis (OR 6.4, 95% CI 3.2–12.7), hypothyroidism (OR 4.3, 95% CI 2.9–6.3), arthralgia (OR 3.5, 95% CI 2.6–4.8) and
vitiligo (OR 3.5, 95% CI 2.3–5.3) were more common with PD-1 mAbs. Comparison of irAE from the three most studied tumour
types in PD-1 mAbs trials [melanoma (n¼ 2048), non-small-cell lung cancer (n¼ 1030) and renal cell carcinoma (n¼ 573)] showed
melanoma patients had a higher frequency of gastrointestinal and skin irAE and lower frequency of pneumonitis.
Discussion: CTLA-4 and PD-1 mAbs have distinct irAE profiles. Different immune microenvironments may drive histology-
specific irAE patterns. Other tumour-dependent irAE profiles may be identified as data emerge from ICI trials.
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Introduction
Immune surveillance involves detection and elimination of can-
cer cells by the immune system [1]. A hallmark of cancer is a fail-
ure of surveillance that leads to tolerance, equilibrium and escape
with the establishment of malignant disease. Examples of mech-
anisms of adaptive immune resistance include downregulation of
major histocompatibility complex antigen expression, secretion
of immunosuppressive cytokines and negative regulation of cyto-
toxic CD8þT cells via checkpoint inhibition [2].
Impressive single agent activity of various immune checkpoint
inhibitors (ICIs) has resulted in regulatory approval of several
agents in a variety of solid tumour indications [3–9]. To enhance
antitumour immune responses, combination strategies that in-
clude ICI with chemotherapy, targeted molecules and other im-
mune-based therapies are being explored. Successful
combination strategies will depend not only on antitumour im-
mune response and survival outcomes, but also on the toxicity
profile and tolerability.
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Immune-related adverse events (irAE) from ICI, differ from
toxicities caused by cytotoxic or molecularly targeted agents.
The time to toxicity may be delayed and not follow a cyclical
pattern as seen with conventional cytotoxics. Mechanisms of
toxicity remain to be defined and may well be heterogeneous be-
tween patients even with the same agent. The over-reactive im-
mune response may be driven by the removal of tolerance by ICI
unmasking low-level self-reactive T cells, macrophage-mediated
toxicity or production of antibodies from activated B cells [2].
These irAE are wide ranging in terms of organs affected and se-
verity. Dermatologic, endocrine, neurologic, gastrointestinal,
respiratory and musculoskeletal toxicities may occur alone or in
constellation. The majority are self-limiting or resolve with im-
munosuppressants such as corticosteroids. Persistent irAE that
do not resolve with corticosteroids require tumour necrosis fac-
tor a receptor antagonists such as infliximab, in the case of col-
itis or mycophenolate in the case of refractory hepatitis,
an inhibitor of purine synthesis in T and B cells. Only a
small minority of irAE do not respond to these immune modu-
lators [10].
We hypothesize that the patterns, range and severity of irAE
may differ between different ICI classes. A better understanding
of irAE would enable better patient management of irAE. It
would also inform the design of future ICI trials particularly
where combinations of agents are being explored and where tol-
erability is key to their success. We conducted a systematic review
of prospective monotherapy trials of ICI. The objective was to
identify and contrast patterns and incidence of irAE based on ICI
class and tumour type.
Materials and methods
Data sources and search strategy
A literature search was carried out using Medline, EMBASE and
COCHRANE databases to identify prospective clinical trials of
ICIs with single agent treatment arms from 2003 to 2015.
Keywords included neoplasm, clinical trials, immune
checkpoint, cytotoxic T-lymphocyte antigen (CTLA-4), pro-
grammed cell death protein-1 (PD-1), its ligand PD-L1 and
specific ICI drug names. The search was conducted in
November 2015.
Study selection
We defined inclusion and exclusion criteria a priori. Two sets of
reviewers (LK and AH or LK and DD) evaluated the titles and ab-
stracts of publications identified by the search strategy, and any
publication thought to be potentially relevant was retrieved in
full. The same set of two reviewers then assessed full publications
for eligibility. Only prospective clinical trials in solid tumours
with single agent treatment arms and those published in English
were included. Reviewers were not blinded to study authors or
outcomes. The decision to include a study for review was made
by consensus between the reviewers (LK, AH and DD). The plan
was that disagreements would be resolved by the third author,
but none occurred.
Data extraction
Data were extracted by paired reviewers (LK and AH or LK and
DD). Disagreements were resolved by consensus. Data extracted
included study size, tumour type, phase of study, ICI class/agent
and year of publication. All treatment-related AEs and AEs of
special interest deemed to be possible immune-related toxicities
were considered to be irAE. The incidence of all grade and
grade3 AE was collected. AEs that were not described as treat-
ment related or possibly treatment related were excluded. Data
were extracted from the main text and supplementary. Where
combination studies were examined, data from the single agent
arms only were extracted.
Study objectives
The primary objective was to determine the frequency of reported
all grade and grade3 irAE from ICI. Secondary aims included a
comparison of irAE across ICI classes and tumour types.
Associations between irAE and other study or treatment-related
factors were also explored.
Statistical analysis
Baseline categorical variables were summarized using frequency
and percentage, and continuous variables were summarized
using mean or median. For each irAE, percentages were reported
and used in all analyses to account for differences in trial size.
Odds ratio (OR) with 95% confidence intervals (CI) were used to
quantify the impact of different tumour types, ICI drugs, or drug
doses to the incidence and severity of each irAE. The P-values
were calculated using the v2 test and presented in contingency
tables. A multivariate logistic regression model was used for ana-
lysis of the association between irAE and clinical variables. These
variables assessed for confounding included tumour type, ICI
drug and drug dose. To capture the detail irAE in different
doses of ICI in each study, trials with multiple doses of ICIs
were separated into multiple arms in the multivariate analysis
model. A P-value <0.05 was considered statistically significant.
No adjustments were made for multiple significance testing.




The literature search identified a total of 5589 publications
(Figure 1). Upon review 5473 publications were excluded leaving
116 ICI trials. This was supplemented by hand searches of meet-
ing proceedings and references in published articles (6 studies).
Of these 122 publications a total of 74 were excluded due to sec-
ondary reporting (n¼ 33), combination studies (n¼ 36), retreat-
ment study with ICI (n¼ 1), neoadjuvant or adjuvant studies
(n¼ 2) or incomplete reporting of irAE (2). Thus, the final total
number of studies included in this review was 48 (supplementary
Table S1, available at Annals of Oncology online).
The most studied tumour type was melanoma in 25 (52%)
studies. Fifty-four percent of trials evaluated an anti-CTLA-4
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agent [9, 11–35], 35% an anti-PD-1 agent [3, 4, 6–8, 36–47] and
4% an anti-PD-L1 ICI [48, 49]. Randomized studies that had a
treatment arm that used single agent ICI comprised 6% of trials
included [50–52]. Phase II studies predominated (40%, n¼ 19)
with only 19% (n¼ 9) being phase III. Eighty-seven percent were
conducted between 2009 and 2015. A total of 6938 patients were
treated in 48 trials but 6869 were assessable for safety. Table 1 de-
tails the characteristics of the trials.
Incidence of all grade and grade3 irAE. Examining irAE only,
the most commonly reported irAE that occurred for all ICI were
endocrine (thyroid disorders such as hypothyroidism and hyper-
thyroidism followed by pituitary and adrenal dysfunction),
gastrointestinal (diarrhoea, colitis, nausea), lung (pneumonitis),
skin (rash, pruritus and vitiligo) and musculoskeletal (arthralgia
and myalgia). Constitutional symptoms of fatigue, pyrexia and
anorexia were also common. Supplementary Table S2, available
at Annals of Oncology online, reports the percentages of these
common toxicities per class of ICI agent.
Incidence of irAE according to ICI class. Grade3 irAE were
more common with CTLA-4 compared with PD-1 ICI (31% ver-
sus 10%; OR 4.0, 95% CI 3.5–4.6). All grades colitis (OR 8.7, 95%
CI 5.8–12.9), hypophysitis (OR 6.5, 95% CI 3.0–14.3) and rash
(OR 2.0, 95% CI 1.8–2.3) were more frequent with CTLA-4 ICI;
whereas pneumonitis (OR 6.4, 95% CI 3.2–12.7), hypothyroid-
ism (OR 4.3, 95% CI 2.9–6.3), arthralgia (OR 3.5, 95% CI 2.6–
4.8) and vitiligo (OR 3.5, 95% CI 2.3–5.3) were more common
with PD-1 monoclonal antibodies (Figure 2).
Incidence of irAE according to histology. Comparison of irAE
from the three most studied tumour types in PD-1 ICI trials
[melanoma (n¼ 2048), non-small-cell lung cancer (NSCLC,
n¼ 1030) and renal cell carcinoma (RCC, n¼ 573)] showed that
melanoma patients had a higher frequency of gastrointestinal and
skin irAE; and lower frequency of pneumonitis compared with
NSCLC. Arthritis and myalgia were more common in melanoma
patients compared with RCC where pneumonitis and dyspnoea
were more prevalent. These results are in Table 2 and Figures 3
and 4. CTLA-4 mAb trials were typically in melanoma or mixed
tumour types; hence, a similar analysis comparing histology-spe-
cific irAE profiles was not feasible.
Differences in incidence of irAE according to ICI dose level.
Where possible, the rates of commonly reported toxicities for each
dose level of an individual ICI agent were evaluated and compared
(supplementary Table S3, available at Annals of Oncology online).
Although a proportional increase in the frequency of irAE was
observed with an increase in dose level, the only irAE that demon-
strated a statistically significant association with dose was
Keywords through MEDLINE/EMBASE/Cochrane
databases: Neoplasm, clinical trial, English, year 2003- Nov








Non-clinical trial papers (n=3251)
Non-Immune checkpoint-related clinical trials (n=165)
Immune checkpoint-related clinical trials
(n=116) + manual search (n=6): n=122
Full manuscripts included in analysis (n=48)
Immune checkpoint-related clinical trials excluded (n=74)
Secondary reporting (n=33)
Combination studies (n=36)
Retreatment with ICI (n=1)
Neoadjuvant or adjuvant studies (n=2)
Incomplete reporting of AEs (n=2)
Biomarker/exploratory studies/preclinical reports (n=138)
Hematological malignancy studies (n=151)
Figure 1. Consort diagram showing the selection process of studies included in the literature review.
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pneumonitis with nivolumab treatment; 10 versus 3 mg (HR 2.76,
95% CI 1.23–6.18). These comparisons are reported in supple-
mentary Table S4, available at Annals of Oncology online.
Multivariable analysis. A multivariate logistic regression model
for the risk of colitis or pneumonitis occurrences was derived
using tumour type (melanoma versus non-melanoma), ICI class
(CTLA4 versus PD-1) and dose [equivalent or lower than
recommended phase II dose (RP2D) versus higher than RP2D
dose]. Only ICI class was significantly associated with a risk of
irAE: CTLA-4 agents had increased risk for the development of
colitis compared with PD-1 agents (OR 3.12, 95% CI 1.06–9.24,
P¼ 0.04) and lower risk of pneumonitis occurrence when com-
pared with PD-1 agents (OR 0.03, 95% CI, 0.01–0.15, P< 0.001).
Results of the multivariable analysis are outlined in Table 3.
Incidence of irAE leading to dose discontinuation and deaths.
Dose discontinuation due to irAE was not consistently reported
nor described in the included clinical trials. When reported, dis-
continuation rates ranged between 3% and 12% in anti-PD-1 tri-
als and between 3% and 25% in anti-CTLA-4 trials. The most
common irAE leading to discontinuation was diarrhoea/colitis.
Supplementary Table S5, available at Annals of Oncology online,
reports irAE leading to death. AEs leading to death were exceed-
ingly rare for anti-PD-1 agents (pembrolizumab, 0.1%; nivolu-
mab 0.3%) and most often secondary to pneumonitis. In the case
of anti-CTLA-4 clinical trials, death were more likely secondary
to gastrointestinal events including diarrhoea, colitis and colonic
perforation (9/29, 31% of grade 5 events).
Discussion
Our study has demonstrated several important new aspects of
irAE that have not been reported before. We have shown that dif-
ferent tumour histologies (melanoma, renal cell and NSCLC)
have a different irAE profile when treated with PD-1 inhibitors.
While intriguing, such a finding should not be a surprise given
that antitumour immune responses differ across patients with
different tumour types treated with the same ICI. Currently the
reasons for this observation are not clear. The tumour micro-
environment (TME), immune infiltrate, adaptive immune re-
sponse and neoantigen formation may be influenced by histology
and is thus one potential explanation for different toxicities
[53–55]. It is not known if the site of metastasis also influences
the irAE pattern, because this level of detail was not reported in
the reviewed studies. Furthermore, comorbidities such as chronic
obstructive airways disease and prior therapies including lung ir-
radiation in patients with NSCLC may have influenced the higher
rates of pneumonitis in these patients when treated with PD-1 in-
hibitors when compared with patients with melanoma. This does
not explain the higher incidence of pneumonitis also observed in
patients with renal cell cancer. This observation raises the inter-
esting possibility that such differential effects may be seen in
other tumour types and across different ICI classes.
Anti-PD-1/PD-L1 mAbs gained FDA approval over the past
year in both cisplatin-refractory head and neck cancers and urothe-
lial carcinomas. Interestingly, first line approval of pembrolizumab
in NSCLC is limited to PD-L1 positivity defined by immunohisto-
chemical staining of at least 50% of cells and non-ALK, non-EGFR
mutant patients [56]. Translational research efforts in these cancers
and in different treatment settings may elucidate differences in the
TME, the effect of tumour heterogeneity both on the TME and the
immune response [57], and the effect of other treatment modalities
on the TME. All of these factors may affect subsequent toxicity.
The identification of specific toxicity profiles related to different
treatment settings will require concerted efforts and large pooled
Table 1. Characteristics of the 48 immune checkpoint inhibitor clinical
trials












Mixed tumour types 7 15
Others (bladder, colorectal, gastro-oesophageal,
liver, ovarian, pancreas)
6 13
Phase of clinical trials
Phase I 14 29
Phase I/II 4 8
Phase II 21 44
Phase III 9 19
CTCAE version used for AE-reporting
CTCAE 2.0 4 8
CTCAE 3.0 19 40












Region in which trial was conducted
Multi-national 20 40
North America 21 46
Europe 5 10
Japan 2 4
Trial patient number recruited per single agent arm
Median 70
Range 9–555
aStudies including both anti-CTLA-4 and anti-PD-1 agents, as single
agents or combinations. Only single agent treatment arms were
included in this analysis.
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datasets for analysis. An added layer of complexity to the inter-
action between TME and tumour cells is the individual patient’s
immune profile. To explore this interaction immunopharmacoge-
nomics combines analysis of the immune response with an indi-
vidual’s pharmacologic responses based on genetic characteristics,
somatic mutations and gene expression profiles. The analysis of
T-cell and B-cell clonality within a patient’s tumour, the relation-
ship to response and toxicity along with other factors such as
the microbiome and crucially the study of autoimmunity will
ultimately aide personalized immune-oncology therapy [58].
As an example, single nucleotide polymorphisms in the PD-1 gene
have been reported to be associated with susceptibility to rheuma-
toid arthritis [59, 60] and thus may predispose these patients to
immune mediated arthralgia.
Overall, our results did not show a dose-dependent increase in
irAE severity or percentage. The majority of irAE included in our
analysis were from recent trials and it may be that investigators
are more aware of and aggressive in their management of irAE.
Thus, earlier detection and wider use of steroids may have af-
fected the rate of grade 3/4 irAE. It should be noted that a recently
reported phase 3 trial comparing 3 versus 10 mg/kg ipilimumab
in metastatic melanoma did show an 50% increase in the rates
of grade 3–5 irAE with the higher dose and an increased death
rate secondary to toxicity [61]. Trials to date (including random-
ized trials) with various doses of anti-PD-1 antibodies have not
shown this difference for these agents [3, 4, 7, 52]. We also
analysed specific commonly occurring irAE, in particular colitis
and pneumonitis to determine whether any factors could predict
the occurrence of these side-effects. These irAE can be fatal and
thus identifying high-risk patients would be informative.
However, apart from PD-1 therapy being associated with pneu-
monitis, our multivariable analysis did not reveal any predictors
of pneumonitis or colitis.
In addition, our review has confirmed observations previously
made. Trials with ICI agents have a wide variety of irAE with the
endocrine, skin and gastrointestinal systems being most com-
monly affected [62, 63]. The irAE pattern is different across ICI
class [62, 63]. This could be driven by different immune cell acti-
vation that can occur with ICI of different class. Furthermore, tis-
sue-related factors may also contribute to irAE, for example
CTLA-4 expression is found in the pituitary accounting for
the greater incidence of hypophysitis with CTLA-4 mAbs [64].
The greater incidence of pneumonitis with therapies targeting the
anti-PD-1 axis may be due to activation of macrophages but the
pattern behind other differences is not clear [65]. Interestingly,
initial protocols of ICI trials precluded patients who had experi-
enced grade3 toxicity with a previous ICI because of the con-
cern that patients would be at higher risk of irAE on the
subsequent ICI. However, the experience of patients off trial has
shown that patients can switch (due to toxicity) from one ICI to
another without further irAE [66]. Patterns of toxicity with par-
ticular ICI class/agents in relation to duration of treatment have
been examined [62, 67–69]. For example, skin toxicity tends to
occur early with both CTLA-4 and anti-PD-1 mAbs. Moreover, it
does appear that the likelihood of toxicity falls but does not dis-
appear, the longer a patient has been treated. We could not exam-
ine the multivariate effect of median duration of treatment on
toxicity, as this was not universally reported. Moreover, due to
the small number of PD-L1 studies it was not possible to do an
adequate comparison between toxicity profiles of anti-PD-1 and
anti-PD-L1 agents. Given the reported patterns of expression of
Pneumonitis
More likely to occur with
CTLA-4 mAb

































Figure 2. The odds ratio (OR) of different immune-related adverse events (all grades) comparing PD-1/PD-L1 versus CTLA-4 immune check-
point inhibitors.
Table 2. Comparison of the incidence of irAE between tumour types for









Colitis 4.2 (1.3–14.0) 0.01 NA (no event for RCC)
Diarrhoea 1.9 (1.5–2.5) <0.001 1.3 (1.1–1.8) 0.04
Pruritus 2.4 (1.9–3.1) <0.001 1.5 (1.2–2.0) 0.003
Rash 1.8 (1.4–2.3) <0.001 1.6 (1.2–2.1) 0.002
Pneumonitis 0.4 (0.3–0.7) <0.001 0.3 (0.2–0.6) <0.001
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these targets, it could be hypothesized that anti-PD-L1 agents
could be associated with less toxicity because of PD-L2 sparing,
which preserves normal immune homeostasis.
Other published meta-analyses on irAE with ICI have exam-
ined patterns and incidence of pneumonitis specifically. Our
findings are consistent with these reports. For example, in one
report [70] of 6360 patients, the incidence of pneumonitis was
increased in NSCLC and RCC with an overall incidence of 2.9%
for all grades and 1.5% for grade 3 or above. In another study of
4496 patients [71], the incidence of all grade pneumonitis was
increased in RCC compared with melanoma, although not for
events of grade 3 and above. When comparing melanoma and
NSCLC, the incidence was higher in NSCLC for both all grade
and grade 3 or above events. In this study, the overall incidence of
pneumonitis was 2.7% for all grades and 0.8% of grade 3 or above
across all histologies.
Deaths due to irAE are not common; however, it is difficult to
determine how frequently irAE lead to discontinuation of treat-
ment. Some toxicities such as skin-related rash or itch resolve
completely with appropriate management whilst others such as
endocrine disorders require replacement treatment long term.
Specific management guidelines exist for ICI agents, although
such recommendations have not been tested in a prospective
randomized setting and represent consensus expert opinion [10].
Corticosteroids remain the initial immunosuppressant of choice
and are administered either intravenously or orally depending on
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Pruritus, diarrhea, rash, pneumonitis: p<0.0001
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Figure 3. The odds ratio (OR) of different immune-related adverse events (all grades) comparing melanoma and non-small cell lung cancer
(NSCLC) anti-PD-1 immune checkpoint inhibitor studies.




Arthragia, hypothyroidism, pneumonitis: p<0.0001
Rash, pruritus, diarrhea, dyspnea: 0.001 <p<0.05























Figure 4. The odds ratio (OR) of different immune-related adverse events (all grades) comparing melanoma and renal cell carcinoma (RCC)
anti-PD-1 immune checkpoint inhibitor studies.






Drug type 3.12 (1.06–9.24) 0.03 (0.007–0.148)
(CTLA-4 versus PD-1/PD-L1) P¼ 0.04 P< 0.001
Tumour type 0.85 (0.28–2.57) 0.51 (0.11–2.41)
(Melanoma versus
non-melanoma)
P¼ 0.78 P¼ 0.40
Higher than RP2D versus
equivalent or lower than RP2D
1.74(0.51–5.94) 2.79 (0.52–15.04)
P¼ 0.38 P¼ 0.23
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irAE, the steroids are slowly tapered over weeks to limit relapse of
the side-effect. ICI dosing is also delayed or skipped during the oc-
currence of an irAE or while patients are receiving steroid therapy
above an equivalent dose of prednisone 10 mg daily. Re-treating pa-
tients with the same ICI after resolution of an irAE should account
for the system affected and the severity of the event. Patients with
skin irAE or endocrinopathies on stable doses of hormone replace-
ment may be re-treated safely. However, re-challenging patients
with life threatening irAE, such pneumonitis or colitis, probably
should be avoided for safety reasons. As combinations of ICI agents
with immune or non-immune therapies are increasingly being
tested in the clinic, it is anticipated that severe, unusual or unex-
pected toxicities could occur, and detailed reporting in the litera-
ture is crucial to help understand and manage them.
Our review included studies over a 12-year period and has sev-
eral limitations. We did not have individual patient data to analyse
and thus our review is subject to the quality of reporting of irAE.
This has previously been shown to be often missing important de-
tails about toxicities [72]. Moreover trials vary in reporting all AEs
to reporting only those that occur above a certain percentage rang-
ing between1% and 5–10%. Experience gained in defining and
managing these toxicities during earlier trials has led to earlier rec-
ognition and better management of irAE in subsequent trials and
thus potentially has decreased the frequency of severe events. The
diagnosis of colitis may also differ between protocols or treatment
centres where biopsy is required by some physicians. While our
analysis involved just under 7000 patients, caution should be taken
in relation to extrapolating these results to other ICI or tumour
types given the limited number of studies included. Previously, it
has been described that the severity and frequency of toxicities are
usually worse in a real world population when compared with the
clinical trial patient sample [73]. Hence, we may have underesti-
mated the true differences of irAE profiles between ICI class or
tumour histology. Different versions of CTCAE may have been
used across studies although this is unlikely to have had a signifi-
cant impact on our findings given that latter versions tended to
include more descriptors and with better harmonization with
Medical Dictionary for Regulatory Activities (MedDRA) termin-
ology. There is for example no major difference between the grad-
ing for pneumonitis and colitis in version 2 compared with version
4. A further limitation in the field as a whole is the definition of an
irAE. There is currently no standardized methodology to deter-
mine whether an AE is an irAE or an AE of other aetiology. Whilst
particular toxicities have emerged through trial experience as being
associated with ICI, such as colitis with CTLA-4 mAbs, others such
as arthritis are yet to be defined clearly [74]. We reported side-ef-
fects as irAE if they were reported as such in the study or if they
were reported as a toxicity of special interest. Typically, the diag-
nostic tests used to define irAE were not provided by the studies.
Thus we cannot confirm if for example, inflammatory arthritis
met specific histological/cytological and radiographic definitions
[74]. Actual frequencies of irAE would be affected by failure to
recognize symptoms that were irAE (under reporting) or if symp-
toms were incorrectly defined as an irAE (over reporting).
This comprehensive review has described several important
new insights and confirmed previous observations about irAE. In
light of this study, we should be mindful that different tumour
types may have different irAE patterns when treated with the
same ICI and this may be more evident when these agents are
utilized in real world patients. Clearly, a more thorough under-
standing of the mechanisms of irAE is needed, which may lead to
the identification of biomarkers to predict the occurrence of tox-
icity in patients or predict those who have irAE that are unlikely
to respond to corticosteroids. These markers could have the po-
tential to impact irAE management. In addition, efforts should
be made to identify clinical factors such as prior treatment or
concomitant comorbidities that could be associated with a higher
risk of irAE. Coupled with better reporting of irAE from clinical
trials, quality of life data must also be captured ideally by a tool
that has been tailored to patients receiving ICI therapy; the en-
deavour to create such a tool is currently being undertaken by
our group. A better understanding of irAE can inform patient
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